Neglected burden of obstructive sleep apnoea: workplace productivity loss in the USA and UK.
Where this comes from
- Record sourced from PubMed, PMID 41735061.
- Also identified by DOI 10.1136/thorax-2025-223550.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study estimates the prevalence and workplace productivity burden of obstructive sleep apnoea (OSA) syndrome in the UK and USA, using self-reported breathing pauses and excessive daytime sleepiness as a proxy. The prevalence of OSA syndrome was 22.8% in the USA and 19.5% in the UK. Annual productivity losses were estimated at US$180.2 billion in the USA and £4.22 billion in the UK. In the UK and USA, individual-level productivity losses exceeded the cost of continuous positive airway pressure (CPAP) treatment, suggesting that improved identification, access to treatment and adherence could yield significant economic benefits in both countries.
Medical subject headings
- Sleep Apnea, Obstructive
- Efficiency
- Cost of Illness
- Workplace